Lemon-flavored

GASTROGRAFIN®
(diatrizoate meglumine and diatrizoate sodium solution USP)

For specific GI imaging applications...

A trusted solution for over 50 years¹
Clinical efficacy and safety help support confidence

Lemon-flavored Gastrografin (diatrizoate meglumine and diatrizoate sodium solution USP) is a palatable, water-soluble, iodinated, radiopaque contrast medium that can be used:

- As an alternative to non–water-soluble barium sulfate agents
- As an adjunct to IV contrast enhancement in computed tomography (CT) of the torso
- In various bowel imaging applications, including CT colonography

INDICATIONS AND USAGE
Gastrografin (Diatrizoate Meglumine and Diatrizoate Sodium Solution) is indicated for radiographic examination of segments of the gastrointestinal tract (esophagus, stomach, proximal small intestine, and colon). The preparation is particularly indicated when a more viscous agent such as barium sulfate, which is not water soluble, is not feasible or is potentially dangerous. Gastrografin may also be used as an adjunct to contrast enhancement in computed tomography of the torso (body imaging); the preparation is indicated, in conjunction with intravenous administration of a radiopaque contrast agent, when unenhanced imaging may not provide sufficient definition in distinguishing normal loops of bowel from adjacent organs or areas of suspected pathology.

CONTRAINDICATIONS
Do not administer to patients with a known hypersensitivity to Gastrografin or any of its components.

IMPORTANT SAFETY INFORMATION
Not for parenteral use; do not inject. Oral or rectal administration only.

It should be kept in mind that serious or anaphylactoid reactions that may occur with intravascular administration of radiopaque contrast agents are theoretically possible following administration by other routes. Patients at increased risk include those with a history of a previous reaction to a contrast medium, patients with a known sensitivity to iodine per se, and patients with a known clinical hypersensitivity (bronchial asthma, hay fever, and food allergies).

Please see accompanying full Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
GASTROGRAFIN® vs OMNIPAQUE™ (iohexol injection) 350: The physicochemical difference is minimal when diluted for use in CT²-⁴

Effect of dilution for use in CT²-⁴

Gastrografin and Omnipaque 350 were diluted 1:40 in water, milk, apple juice, Crystal Light®, and ginger ale (diluents typically used in clinical CT practice during oral administration for GI lumen enhancement).

- Upon the 1:40 dilution of both contrast agents with the various drinks mentioned above, the diluent contributed to the final osmolality and viscosity of the administered drink
- For each base diluent, the addition of the contrast agent resulted in a minimal effect on the overall osmolalities and viscosities of the solutions

*An osmolality and viscosity comparison of the properties of Gastrografin vs Omnipaque 350 when mixed with various diluents for use in CT. As packaged and labeled, the osmolality of Gastrografin is about 2.5x greater than that of Omnipaque 350.
INDICATIONS AND USAGE
Gastrografin (Diatrizoate Meglumine and Diatrizoate Sodium Solution) is indicated for radiographic examination of segments of the gastrointestinal tract (esophagus, stomach, proximal small intestine, and colon). The preparation is particularly indicated when a more viscous agent such as barium sulfate, which is not water soluble, is not feasible or is potentially dangerous. Gastrografin may also be used as an adjunct to contrast enhancement in computed tomography of the torso (body imaging); the preparation is indicated, in conjunction with intravenous administration of a radiopaque contrast agent, when unenhanced imaging may not provide sufficient definition in distinguishing normal loops of bowel from adjacent organs or areas of suspected pathology.

CONTRAINDICATIONS
Do not administer to patients with a known hypersensitivity to Gastrografin or any of its components.

IMPORTANT SAFETY INFORMATION
Not for parenteral use; do not inject. Oral or rectal administration only.

It should be kept in mind that serious or anaphylactoid reactions that may occur with intravascular administration of radiopaque contrast agents are theoretically possible following administration by other routes. Patients at increased risk include those with a history of a previous reaction to a contrast medium, patients with a known sensitivity to iodine per se, and patients with a known clinical hypersensitivity (bronchial asthma, hay fever, and food allergies).

Please see accompanying full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.


Gatrografin is a registered trademark of E-Z-EM, Inc., a wholly-owned subsidiary of Bracco Diagnostics Inc. Omnipaque is a trademark of GE Healthcare. Crystal Light is a registered trademark of Kraft Foods.